Funder: The Association for Frontotemporal Degeneration
Due Dates (Anticipated): March 2026 (Letter of Intent) | June 2026 (Full Proposal)
Funding Amounts: Up to $2,500,000 total over 1–3 years, based on stage and scope; milestone-based payments.
Summary: Supports early-stage clinical trials for frontotemporal degeneration (FTD) therapies, emphasizing mechanism-driven research, biomarker integration, and innovative trial designs.
Key Information: All dates are projected; confirm on the program page for updates.